SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Alexander M. Walker, Caihua Liang, C. Robin Clifford, Crawford Parker, Allen Feldman, Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors, Pharmacoepidemiology and Drug Safety, 2014, 23, 4
  2. 2
    David J. Graham, Esther H. Zhou, Stephen McKean, Mark Levenson, Katlyn Calia, Kate Gelperin, Xiao Ding, Thomas E. MaCurdy, Chris Worrall, Jeffrey A. Kelman, Cardiovascular and mortality risk in elderly Medicare beneficiaries treated with olmesartan versus other angiotensin receptor blockers, Pharmacoepidemiology and Drug Safety, 2014, 23, 4
  3. 3
    Ivan Stratov, Justin Denholm, Stephen J. Kent, Azithromycin: more lethal than chloramphenicol?, Sexual Health, 2013, 10, 2, 179

    CrossRef

  4. 4
    David J. Graham, James R. Williams, Ya-Hui Hsueh, Katlyn Calia, Mark Levenson, Simone P. Pinheiro, Thomas E. MaCurdy, David Shih, Chris Worrall, Jeffrey A. Kelman, Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone, Movement Disorders, 2013, 28, 4
  5. 5
    Daniel H. Solomon, Jeffrey R. Curtis, Kenneth G. Saag, Joyce Lii, Lang Chen, Leslie R. Harrold, Lisa J. Herrinton, David J. Graham, Mary K. Kowal, Bindee Kuriya, Liyan Liu, Marie R. Griffin, James D. Lewis, Jeremy A. Rassen, Cardiovascular Risk in Rheumatoid Arthritis: Comparing TNF-α Blockade with Nonbiologic DMARDs, The American Journal of Medicine, 2013, 126, 8, 730.e9

    CrossRef

  6. 6
    Wayne A. Ray, Katherine T. Murray, Vivian Kawai, David J. Graham, William O. Cooper, Kathi Hall, Charles Michael Stein, Propoxyphene and the risk of out-of-hospital death, Pharmacoepidemiology and Drug Safety, 2013, 22, 4
  7. 7
    Chi-Un Pae, Sertindole: dilemmas for its use in clinical practice, Expert Opinion on Drug Safety, 2013, 12, 3, 321

    CrossRef

  8. You have free access to this content8
    Leonardo Tamariz, Thomas Harkins, Vinit Nair, A systematic review of validated methods for identifying ventricular arrhythmias using administrative and claims data, Pharmacoepidemiology and Drug Safety, 2012, 21,
  9. 9
    Wayne A. Ray, Katherine T. Murray, Kathi Hall, Patrick G. Arbogast, C. Michael Stein, Azithromycin and the Risk of Cardiovascular Death, New England Journal of Medicine, 2012, 366, 20, 1881

    CrossRef

  10. 10
    Jamie L. Geier, Onur N. Karayal, Michael Lewis, John A. Camm, Martin Keane, Charlotte ME. Kremer, Sheela Kolluri, Robert Reynolds, Sybil Eng, Brian L. Strom, Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up: the ziprasidone observational study of cardiac outcomes (ZODIAC), Pharmacoepidemiology and Drug Safety, 2011, 20, 11
  11. 11
    Daniel Mines, Commentary on the validation studies of sudden cardiac death and ventricular arrhythmia by Hennessy et al. and Chung et al., Pharmacoepidemiology and Drug Safety, 2010, 19, 6
  12. 12
    Current awareness: Pharmacoepidemiology and drug safety, Pharmacoepidemiology and Drug Safety, 2010, 19, 10
  13. 13
    Wayne A. Ray, Katherine T. Murray, C. Michael Stein, Reply to “commentary…”, Pharmacoepidemiology and Drug Safety, 2010, 19, 6